- Home
- WGRX vs IXHL Comparison
WGRX vs IXHL Comparison
Compare WGRX & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- IXHL
- Stock Information
- Founded
- WGRX 2022
- IXHL 2001
- Country
- WGRX United States
- IXHL Australia
- Employees
- WGRX N/A
- IXHL N/A
- Industry
- WGRX Other Pharmaceuticals
- IXHL
- Sector
- WGRX Health Care
- IXHL
- Exchange
- WGRX Nasdaq
- IXHL Nasdaq
- Market Cap
- WGRX 60.2M
- IXHL 49.1M
- IPO Year
- WGRX 2025
- IXHL N/A
- Fundamental
- Price
- WGRX $0.55
- IXHL $0.33
- Analyst Decision
- WGRX
- IXHL
- Analyst Count
- WGRX 0
- IXHL 0
- Target Price
- WGRX N/A
- IXHL N/A
- AVG Volume (30 Days)
- WGRX 2.3M
- IXHL 17.0M
- Earning Date
- WGRX 11-19-2025
- IXHL 11-14-2025
- Dividend Yield
- WGRX N/A
- IXHL N/A
- EPS Growth
- WGRX N/A
- IXHL N/A
- EPS
- WGRX N/A
- IXHL N/A
- Revenue
- WGRX $34,077,635.00
- IXHL $12,000.00
- Revenue This Year
- WGRX N/A
- IXHL $1,188.37
- Revenue Next Year
- WGRX N/A
- IXHL N/A
- P/E Ratio
- WGRX N/A
- IXHL N/A
- Revenue Growth
- WGRX 495.93
- IXHL N/A
- 52 Week Low
- WGRX $0.34
- IXHL $0.08
- 52 Week High
- WGRX $7.04
- IXHL $2.25
- Technical
- Relative Strength Index (RSI)
- WGRX 46.02
- IXHL 42.93
- Support Level
- WGRX $0.44
- IXHL $0.30
- Resistance Level
- WGRX $0.71
- IXHL $0.34
- Average True Range (ATR)
- WGRX 0.07
- IXHL 0.02
- MACD
- WGRX 0.00
- IXHL 0.00
- Stochastic Oscillator
- WGRX 44.15
- IXHL 38.66
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.